Consensus Cloud Solutions, Inc. · NASDAQ:CCSI
Consensus Cloud Solutions — Goldman Sachs 45th Annual Global Healthcare Conference (June 2024)
18 slides from Consensus Cloud Solutions's conference presentation, Jun 13, 2024
Slide 1: Goldman Sachs 45th Annual Global Healthcare Conference
GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE JUNE 13TH 2024
Slide 2: Risk Factors & Other Information
Risk Factors & Other Information Industry, Market and Other Data Certain information contained in this presentation concerning our industry and the markets in which we operate, The following factors, among others, could cause our business, prospects, financial condition, operating results and includ
Slide 3: Today's Presenters
Today’s Presenters Scott Turicchi Johnny Hecker CEO CRO & EVP, Operations ©2024 Consensus Cloud Solutions Inc. All rights reserved. www.consensus.com 3
Slide 4: Business Overview
BUSINESS OVERVIEW consensus
Slide 5: Our Mission
Our Mission Be the trusted global source for the transformation, enhancement and secure exchange of digital information ©2024 Consensus Cloud Solutions Inc. All rights reserved. www.consensus.com 5
Slide 6: Consensus Focus on Healthcare & Interoperability
Consensus Focus on Healthcare & Interoperability Our Offering Product Evolution to Healthcare Interoperability Leading provider of secure data delivery for enterprise and healthcare interoperability 2010 2020 2021 2023 and Beyond Serve the healthcare sector and other highly regulated industries Prod
Slide 7: Consensus is the Market Leader
Consensus is the Market Leader 2,000+ ~75% ~100% Substantial Presence in % New Sales From the High Revenue Enterprise Organizations Healthcare Sector Visibility Strategic customers include 7 of the top We serve 4 of the top 10 Healthcare ~100% of our revenues are 10 Fortune 500 companies Companies i
Slide 8: Healthcare Focus
HEALTHCARE FOCUS consensus
Slide 9: Secure Information Exchange Continues to Rely on Fax Protocol
Secure Information Exchange Continues to Rely on Fax Protocol Use Cases 230k+ 85k+ 6k+ Record Payer Physician Referrals Pharmacies Hospitals Sharing Communication Practices 200k+ 103k+ 6k Communicating Labs / Pharmacy Clinical Post Acute Insurance Tests / Results Communication Labs Facilities Compan
Slide 10: Consensus' Solutions Tailored To Address Interoperability Pain Points
Consensus’ Solutions Tailored To Address Interoperability Pain Points Business Goal Products Use Case / Value Proposition Bridge the gap between • Verified endpoints across ecosystem multiple systems, standards, • Single API community sharing and data sets • Compatible across protocols • Extractive A
Slide 11: Consensus Customer Continuum Provides Insight and Opportunity
Consensus Customer Continuum Provides Insight and Opportunity ECOMMERCE SMB LARGE ACCOUNTS STRATEGIC ACCOUNTS Sales Motion Self Service Inside Sales Inside Sales and Field Sales Field Sales Web Marketing, Inbound Call, Web Marketing, ABM, Channel, Trade Referral/Networking, Trade Lead Sources Web Ma
Slide 12: Financial Highlights
FINANCIAL HIGHLIGHTS consensus
Slide 13: LTM Q1 2024 Financial Metrics
LTM Q1 2024 Financial Metrics Revenue Non-GAAP Adj. EBITDA Non-GAAP Adj. EPS $364.6M $5.53 $359.3M $192.4M $190.4M $5.11 -1.5% 8.2% -1.0% EBITDA % EBITDA % 52.7% 53.0% LTM Q1’23 LTM Q1’24 LTM Q1’23 LTM Q1’24 LTM Q1’23 LTM Q1’24 LTM Q1 2024 Metrics Benefited Significantly from Q1 2024 Performance, Whic
Slide 14: Cash Generation and Capital Allocation Strategy
Cash Generation and Capital Allocation Strategy
Slide 15: LTM Q1 2024 Strong Cash Generation Supports Capital Allocation Strategy
LTM Q1 2024 Strong Cash Generation Supports Capital Allocation Strategy Capital Allocation Priorities • Reduce Gross debt to EBITDA ratio to < 3x in anticipation of our first tranche maturing October, 2026 • November 2023 board approved 3 year, $300M Bond Repurchase program • Opportunistic share repu
Slide 16: $300M Board Approved Bond Repurchase Program
$300M Board Approved Bond Repurchase Program Debt to EBITDA Leverage 2026 6.0%: $305M $305M $305M $279M $261M 2028 6.5%: $500M $500M $500M $455M $418M Total Debt: $805M $805M $805M $734M $679M (1) (1) Represents 3/31/24 combined debt balance on 6.0% and 6.5% notes, excluding deferred issuance costs
Slide 17: Guidance
Guidance consensus
Slide 18: Reaffirming Full Year and Q2 2024 Guidance Range
Reaffirming Full Year and Q2 2024 Guidance Range FY2024(1) Guidance Range Q2’24(1) Guidance In Millions, except EPS GUIDANCE Low Midpoint High Low Midpoint High Revenue $ 338 $ 345 $ 353 $ 84.5 $ 86.5 $ 88.5 Adj. Non-GAAP EBITDA $ 182 $ 188 $ 194 $ 46.0 $ 47.5 $ 49.0 Adj. Non-GAAP EPS(1) $ 5.08 $ 5.20